Chronic Consequences of Uncomplicated Yersinia Enterocolitica Infection: A Retrospective Study (2004) of Military Recruits Previously (1987) Screened for Antibodies to Yersinia Enterocolitica O:3

Arve Sæbø, Karin Nygard, Georg Kapperud, Jørgen Lassen

.

DOI: 10.4236/ijcm.2011.22024                

Abstract

In 1987, a serological survey among 755 male Norwegian military recruitsshowed that 68 (9.0%) had IgG (7.4%) and / or IgA (4.5%) antibodiesto Y.enterocolitica O:3, consistent with previous infection.In 2004,433 of the former recruits (mean age 37.5 years, range 35 - 42 years) answered a questionnaire, in order to investigatedevelopment of possible chronic disorders and complaints related to uncomplicated Y.enterocolitica infection. The questionnaire covered per-sonal and demographic data, behavioral risk factors, and possible chronic complaints related to yersiniosis.Among the 433 responders, 51 (11.8%) were seropositive for IgG or IgA in the 1987 survey, 380 were seronegative, and 2 had ambiguous results.No difference was observed between the seropositive and seronegativegroups regarding education, annual income, general behavioral risk factors like smoking, alcohol consumption, physical activity, and dietary parameters; or diagnosed chronic illness. However, the seropositives weresignificantly more likely than the seronegatives to report recurrent diarrhea, painful or swollen joints, and muscle pain. Also, presence of all three complaints was more common among seropositives. Conclusion: The present study shows that uncomplicated Y.enterocolitica O:3 infection is a risk factor regarding future development of chronic complaintssuch as diarrhea, and joint and muscle complaint.

Keywords

Chronic Complaint (Diarrhea, Painful / Swollen Joints, Muscle Pain)

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	[1] M. G. Carlsson, H. Ryd and N. H. Sternby, “A Case of Human Infection with Pasteurellapseudotuberculosis X,” Acta Pathologica Microbiologica Scandinavica, Vol. 62, 1964, pp. 128-132.
[2]	[2] B. Nilehn and B. Sj?str?m, “Studies on Yersinia Enterocolitica. Occurence in Various Groups of Acute Abdominal Disease,” Acta Pathologica Microbiologica Scandinavica, Vol. 71, No. 4, 1967, pp. 612-628. doi:10.1111/j.1699-0463.1967.tb05182.x
[3]	[3] B. Arvastson, K. Damgaard and S. Winblad, “Clinical Symptoms of Infection with Yersinia Enterocolitica,” Scandinavian Journal of Infectious Diseases, Vol. 3, No. 1, 1971, pp. 37-40.
[4]	[4] P. Ahvonen, “Human Yersiniosis in Finland, II. Clinical Features,” Annals of Clinical Research, Vol. 4, No. 1, 1972, pp. 39-48.
[5]	[5] A. Saebo and J. Lassen, “A Survey of Acute and Chronic Disease Associated with Yersinia Enterocolitica Infection. A Norwegian 10-year Follow-up Study on 458 Hospitalized Patients,” Scandinavian Journal of Infectious Diseases, Vol. 23, No. 5, 1991, pp. 517-527. doi:10.3109/00365549109105172
[6]	[6] K. Aho, P. Ahvonen, A. Lassus, K. Sievers and A. Tiilikainen, “HL-A27 in Reactive Arthritis. A Study of Yersinia Arthritis and Reiter’s Disease,” Arthritis & Rheumatism, Vol. 17, No. 5, 1974, pp. 521-526. doi:10.1002/art.1780170505
[7]	[7] M. Leirisalo, G. Skylv, M. Kousa, L. M. Voipo-Pulkki , H. Souranta, M. Nissila, et al., “Follow-up Study on Patients with Reiter’s Disease and Reactive Arthritis, with Special Reference to HLA-B27,” Arthritis & Rheumatism, Vol. 25, No. 3, 1982, pp. 249-259. doi:10.1002/art.1780250302
[8]	[8] M. Friedberg, T. Denneberg, C. Brun, J. H. Larsen, S. Larsen, “Glomerulonephritis in Infection with Yersinia Enterocolitica O-serotype 3. II. The Incidence and Immunological Features of Yersinia Infection in a Consecutive Glomerulonephritis Population,” Acta Medica Scandinavica, Vol. 209, No. 1-6, 1981, pp. 103-110. doi:10.1111/j.0954-6820.1981.tb11560.x
[9]	[9] K. A. Sotaniemi, “Neurologic Complications Associated with Yersiniosis,” Neurology, Vol. 33, No. 1, 1983, pp. 95-97.
[10]	[10] A. Saebo, “Liver Affection Associated with Yersinia Enterocolitica Infection,” Acta Chirurgica Scandinavica, Vol. 143, No. 7-8, 1977, pp. 445-450.
[11]	[11] A. Saebo, E. Vik, O. J. Lange and L. Matuszkiewicz, “Inflammatory Bowel Disease Associated with Yersinia Enterocolitica O:3 Infection,” European Journal of Internal Medicine, Vol. 16, No. 3, 2005, pp. 176-182. doi:10.1016/j.ejim.2004.11.008
[12]	[12] M. Leirisalo-Repo and H. Souranta, “Ten-Year Follow-up Study of Patients with Yersinia Arthritis,” Arthritis & Rheumatism, Vol. 31, No. 4, 1988, pp. 533-537. doi:10.1002/art.1780310410
[13]	[13] H. Lindholm and R. Visakorpi, “Late Complications after a Yersinia Enterocolitica Epidemic: A Follow up Study”. Annals of the Rheumatic Diseases, Vol. 50, No. 10, 1991, pp. 694-696. doi:10.1136/ard.50.10.694
[14]	[14] J. A. A. Hoogkamp-Korstanje, J. de Koning and J. Heesemann, “Persistence of Yersinia Enterocolitica in Man,” Infection, Vol. 16, No. 2, 1988, pp. 81-85. doi:10.1007/BF01644307
[15]	[15] L. Vold and K. Nygard, “Yersiniosis in Norway 2002,” MSIS-rapport, (In Norwegian), Communicable Disease Report, Norwegian Institute of Public Health, Oslo, Vol. 31, 2003, pp. 40.
[16]	[16] F. Kallinowski, A. Wassmer, M. A. Hoffmann, D. Harmsen, J. Heesemann, H. Karch, et al., “Prevalence of Enteropatogenic Bacteria in Surgically Treated Chronic Inflammatory Bowel Disease,” Heptogastroenterology, Vol. 45, No. 23, 1998, pp. 1552-1558.
[17]	[17] J. A. Hoogkamp-Korstanje, J. de Koning, J. Heesemann , J. J. Festen, P. M. Houtman and P. L. van Oyen, “Influence of Antibiotics on IgA and IgG Response and Persistence of Yersinia Enterocolitica in Patients with Yersinia-Associated Spondylarthropathy,” Infection, Vol. 20, No. 2, 1992, pp. 53-57. doi:10.1007/BF01711062
[18]	[18] B. E. Wenzel, J. Heesemann, A. Heufelder, T. F. Franke S. Grammerstorf, R. Stemerowicz, et al., “Ente- ropathogenic Yersinia Enterocolitica and Organ- Specific Autoimmune Disease in Man,” Contrib Microbiol Immunol, Vol. 12, 1991, pp. 80-88.
[19]	[19] A. Saebo, G. Kapperud, J. Lassen and J. O. Waage “Prevalence of Antibodies to Yersinia Enterocolitica O:3 among Norwegian Military Recruits: Association with Risk Factors and Clinical Manifestations,” European Journal of Epidemiology, Vol. 10, No. 6, 1994, pp. 749-755. doi:10.1007/BF01719293
[20]	[20] A. Saebo and J. Lassen, “Acute and chronic Gastrointestinal Manifestations Associated with Yersinia Infection. A Norwegian 10-year Follow-up Study on 458 Hospitalized Patients,” Annals of Surgery, Vol. 215, No. 3, 1992, pp. 250-255. doi:10.1097/00000658-199203000-00009
[21]	[21] G. Vantrappen, E. Ponette, K.Geboes, P. Bertrand, “Yersinia Enteritis and Enterocolitis: Gastroenterological Aspects,” Gastroenterology, Vol. 72, No. 2, 1977, pp. 220-227.
[22]	[22] A. Saebo, “The Yersinia Enterocolitica Infection in Acute Abdominal Surgery: A Clinical Study with a 5 Year Follow-up Period,” Annals of Surgery, Vol. 198, No. 6, 1983, pp. 760-765. doi:10.1097/00000658-198312000-00015
[23]	[23] K. Granfors, M. Viljanen, A. Tiilikainen, A. Toivanen “Persistence of IgM, IgG, and IgA antibodies to Yersinia in Yersinia arthritis,” Journal of Infectious Diseases, Vol. 141, No. 4, 1980, pp. 424-249. doi:10.1093/infdis/141.4.424
[24]	[24] J. H. Larsen, S. H. Hartzen and M. Parm, “The Determination of Specific IgA-Antibodies to Yersinia Enterocolitica and their Role in Enteric Infections and their Complications,” Acta Pathologica Microbiologica Scandinavica Series B: Microbiology, Vol. 93, No. 1-6, 1985, pp. 331-339.
[25]	[25] J. A. A. Hoogkamp-Korstanje, H. Moesker, G. A. W. Bruyn, “Ciprofloxacin v Placebo for Treatment of Yersinia Enterocolitica Triggered Reactive Arthritis,” Annals of the Rheumatic Diseases, Vol. 59, No. 11, 2000, pp. 914-917. doi:10.1136/ard.59.11.914